These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 26581715)

  • 21. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
    Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
    Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells.
    Martín-Rufián M; Nascimento-Gomes R; Higuero A; Crisma AR; Campos-Sandoval JA; Gómez-García MC; Cardona C; Cheng T; Lobo C; Segura JA; Alonso FJ; Szeliga M; Albrecht J; Curi R; Márquez J; Colquhoun A; Deberardinis RJ; Matés JM
    J Mol Med (Berl); 2014 Mar; 92(3):277-90. PubMed ID: 24276018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Associated gastroenteropancreatic neuroendocrine tumours to familiar syndromes].
    Lecumberri Pascual E
    Endocrinol Nutr; 2009 Apr; 56 Suppl 2():10-5. PubMed ID: 19627764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.
    Dizdar L; Oesterwind KA; Riemer JC; Werner TA; Mersch S; Möhlendick B; Schütte SC; Verde PE; Raba K; Topp SA; Stoecklein NH; Esposito I; Knoefel WT; Krieg A
    Oncotarget; 2017 Jan; 8(5):8369-8382. PubMed ID: 28039474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.
    Vicentini C; Fassan M; D'Angelo E; Corbo V; Silvestris N; Nuovo GJ; Scarpa A
    Molecules; 2014 Feb; 19(2):2458-68. PubMed ID: 24566314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.
    Briest F; Berg E; Grass I; Freitag H; Kaemmerer D; Lewens F; Christen F; Arsenic R; Altendorf-Hofmann A; Kunze A; Sänger J; Knösel T; Siegmund B; Hummel M; Grabowski P
    Oncotarget; 2015 Apr; 6(10):8185-99. PubMed ID: 25797272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors.
    Oktay E; Yalcin GD; Ekmekci S; Kahraman DS; Yalcin A; Degirmenci M; Dirican A; Altin Z; Ozdemir O; Surmeli Z; Diniz G; Ayhan S; Bulut G; Erdogan A; Uslu R
    J BUON; 2019; 24(2):779-790. PubMed ID: 31128036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.
    Kawasaki K; Fujii M; Sato T
    Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
    Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
    Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
    Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutaminase Affects the Transcriptional Activity of Peroxisome Proliferator-Activated Receptor γ (PPARγ) via Direct Interaction.
    de Guzzi Cassago CA; Dias MM; Pinheiro MP; Pasquali CC; Bastos ACS; Islam Z; Consonni SR; de Oliveira JF; Gomes EM; Ascenção CFR; Honorato R; Pauletti BA; Indolfo NC; Filho HVR; de Oliveira PSL; Figueira ACM; Paes Leme AF; Ambrosio ALB; Dias SMG
    Biochemistry; 2018 Nov; 57(44):6293-6307. PubMed ID: 30295466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors.
    Sampedro-Núñez M; Serrano-Somavilla A; Adrados M; Cameselle-Teijeiro JM; Blanco-Carrera C; Cabezas-Agricola JM; Martínez-Hernández R; Martín-Pérez E; Muñoz de Nova JL; Díaz JÁ; García-Centeno R; Caneiro-Gómez J; Abdulkader I; González-Amaro R; Marazuela M
    Sci Rep; 2018 Dec; 8(1):17812. PubMed ID: 30546030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs.
    Lee ME; Tepede AA; Mandl A; Weinstein LS; Del Rivero J; Agarwal SK; Blau JE
    J Mol Endocrinol; 2020 Aug; 65(2):R1-R17. PubMed ID: 32384260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors.
    Malczewska A; Kidd M; Matar S; Kos-Kudla B; Modlin IM
    Neuroendocrinology; 2018; 107(1):73-90. PubMed ID: 29566385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nutritional Complications and the Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Laing E; Kiss N; Michael M; Krishnasamy M
    Neuroendocrinology; 2020; 110(5):430-442. PubMed ID: 31550712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glutamine in neoplastic cells: focus on the expression and roles of glutaminases.
    Szeliga M; Obara-Michlewska M
    Neurochem Int; 2009; 55(1-3):71-5. PubMed ID: 19428809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.
    Viol F; Sipos B; Fahl M; Clauditz TS; Amin T; Kriegs M; Nieser M; Izbicki JR; Huber S; Lohse AW; Schrader J
    Cell Oncol (Dordr); 2022 Dec; 45(6):1401-1419. PubMed ID: 36269546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.